BUY NOVOSARM – LIGANDROL (LGD-4033) (20 MG/ML – 30 ML)
MAIN PRODUCT DESCRIPTION
NovoSARM – Ligandrol (LGD-4033) 20 mg/ml contains LGD-4033, also known as Ligandrol, a selective androgen receptor modulator (SARM) developed as an investigational compound. The supplied product information describes Ligandrol as a compound designed to interact selectively with androgen receptors and discusses research involving skeletal muscle, lean body mass, strength and endocrine effects.
LGD-4033 differs pharmacologically from conventional anabolic-androgenic steroids because it was developed to selectively interact with the androgen receptor rather than acting as a traditional testosterone ester or anabolic steroid. The supplied material states that Ligandrol has high affinity for the androgen receptor and has been investigated for anabolic activity in muscle and bone.
Product Specifications
- Product: NovoSARM – Ligandrol
- Alternative name: LGD-4033
- Strength: 20 mg/ml
- Pack size: 30 ml
- Active compound: LGD-4033 (Ligandrol)
- Dosage form: Liquid preparation with dropper
- Route: Oral, according to supplied information
- Manufacturer supplied: Novosarm, Switzerland
- Product category: SARM
- Regulatory status: Not supplied as an approved medicinal product
Pharmacological Background
Ligandrol is a synthetic compound developed to interact with the androgen receptor (AR). The androgen receptor is a nuclear receptor involved in signalling pathways responsible for numerous androgen-dependent physiological effects.
When an androgen receptor modulator interacts with this receptor, it can influence the transcription of genes involved in androgen-responsive tissues. Research into SARMs has focused on whether selective receptor activity can produce effects in skeletal muscle and bone while limiting activity in other tissues.
The supplied source describes LGD-4033 as having strong androgen-receptor affinity and selectivity. However, claims that it is substantially more anabolic than testosterone or that it is free from the adverse effects associated with anabolic steroids are not established safety conclusions and should not be presented as guarantees.
Research on Lean Body Mass
The supplied information refers to clinical research in which LGD-4033 produced dose-dependent changes in total testosterone and increases in lean body mass during short-term study periods.
The source states that testosterone suppression was observed over approximately 21 days of administration. This is an important finding because it demonstrates that, despite its selective receptor activity, LGD-4033 can influence the endocrine system.
The supplied research also reported that some participants experienced increases in lean body mass. The results did not consistently demonstrate reductions in body fat, meaning that claims that Ligandrol reliably produces fat loss should not be treated as established.
Strength and Muscle Research
The supplied material describes research in which changes in strength-related measures, including stair-climbing speed and power, were observed. These findings are relevant to scientific interest in the relationship between androgen-receptor activation and skeletal muscle function.
However, the available information supplied here does not establish long-term improvements in athletic performance or guarantee muscle or strength gains in individual users.
Endocrine Effects
One of the most important observations described in the supplied material is suppression of endogenous testosterone.
The source states that total testosterone decreased in a dose-dependent manner during the research period. It also reports that hormone levels returned toward baseline after discontinuation, with baseline recovery described by approximately day 56 in the referenced study.
These findings are clinically relevant because they demonstrate that LGD-4033 is not hormonally neutral. Although marketed in some contexts as a selective alternative to anabolic steroids, its activity can still affect the body’s normal endocrine regulation.
Pharmacokinetics
The supplied information reports an elimination half-life of approximately 24–36 hours.
The relatively prolonged half-life means that LGD-4033 can remain pharmacologically active after administration. The exact pharmacokinetic profile may vary depending on formulation, dose and individual physiological characteristics.
No additional pharmacokinetic parameters have been added beyond those supplied.
Safety Considerations
The source material states that adverse effects were not noted in one particular short-term study. This should not be interpreted as evidence that LGD-4033 is universally safe or free from adverse effects.
Short-term clinical observations cannot establish long-term safety. Potential endocrine consequences are particularly important because testosterone suppression was documented in the supplied research.
The product should therefore not be described as non-toxic, risk-free or safer than anabolic steroids without comprehensive evidence supporting such claims.
Bodybuilding and Fitness Claims
The supplied source describes Ligandrol as being used or promoted for bulking, body recomposition, cutting, endurance and muscle development.
These are fitness-related claims rather than established medical indications. The evidence supplied does not establish LGD-4033 as an approved treatment for obesity, muscle wasting, athletic performance or body composition.
The source also contains recommendations concerning cycles, dropper measurements and post-cycle therapy or testosterone boosters. These instructions have not been reproduced as dosing recommendations because LGD-4033 is an investigational SARM and the supplied information does not establish an authorised therapeutic regimen.
Regulatory Status
The supplied material identifies Ligandrol as a SARM but does not provide an EU marketing authorisation, national marketing authorisation number or approved therapeutic indication for this specific product.
Accordingly, NovoSARM – Ligandrol should not be described as an approved medicine, prescription treatment or officially authorised bodybuilding product.
Important Research Notice
LGD-4033 (Ligandrol) is an investigational SARM. Research has examined its interaction with androgen receptors, lean body mass, strength and endocrine function, but the supplied information does not establish long-term clinical safety or an approved therapeutic use.
In particular, the documented suppression of testosterone should not be overlooked when describing the compound. Claims that LGD-4033 is free from the adverse effects associated with conventional anabolic steroids are not supported sufficiently by the supplied information.
This product information is based on the source material provided and is intended as neutral scientific and product information rather than medical advice or instructions for non-prescribed use.
